At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNTX BioNTech SE
Trading 04-01 11:01:48 EDT
90.03
+1.15
+1.29%
High90.45Low88.76Vol135.99K
Open89.78D1 Closing88.88Amplitude1.91%
Mkt Cap22.60BTradable Cap9.45BTotal Shares251.00M
T/O12.21MT/O Rate0.13%Tradable Shares105.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Belgium Court Orders Romania to Take Delivery of 600 Mln Euros Worth of Pfizer Covid Vaccines
THOMSON REUTERS  ·  21:13
Belgium Court Orders Romania to Take Delivery of 600 Mln Euros Worth of Pfizer Covid Vaccines
Stock Track | BioNTech SE Soars 5.03% Intraday on Maintained Buy Rating Despite Target Price Cut
Stock Track  ·  03:22
Stock Track | BioNTech SE Soars 5.03% Intraday on Maintained Buy Rating Despite Target Price Cut
BioNTech Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-31 19:09
BioNTech Is Maintained at Buy by HC Wainwright & Co.
BioNTech price target lowered to $130 from $140 at H.C. Wainwright
TIPRANKS  ·  03-31 18:16
BioNTech price target lowered to $130 from $140 at H.C. Wainwright
De.mem Director Restructures Shareholding Without Changing Overall Stake
TIPRANKS  ·  03-31 13:49
De.mem Director Restructures Shareholding Without Changing Overall Stake
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires Live  ·  03-30 23:07
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Equinor Discloses Small Share Sale by Person Related to Board Member
TIPRANKS  ·  03-28
Equinor Discloses Small Share Sale by Person Related to Board Member
BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next
TIPRANKS  ·  03-28
BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next
BioNTech filed initial beneficial ownership statement; Director Rudolf Staudigl reports 400 ordinary shares
Reuters  ·  03-26
BioNTech filed initial beneficial ownership statement; Director Rudolf Staudigl reports 400 ordinary shares
BioNTech filed an initial beneficial ownership statement; CFO Ramon Zapata Gomez reports no securities beneficially owned
Reuters  ·  03-26
BioNTech filed an initial beneficial ownership statement; CFO Ramon Zapata Gomez reports no securities beneficially owned
BioNTech files initial beneficial ownership statement; Chief People Officer Kylie Jimenez reports no securities owned
Reuters  ·  03-26
BioNTech files initial beneficial ownership statement; Chief People Officer Kylie Jimenez reports no securities owned
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Biomea Fusion (BMEA)
TIPRANKS  ·  03-25
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Biomea Fusion (BMEA)
BioNTech publishes 2025 sustainability report highlighting 50% COVID-19 vaccine market share
Reuters  ·  03-24
BioNTech publishes 2025 sustainability report highlighting 50% COVID-19 vaccine market share
BioNTech FY 2025 net loss widens 70.83% to EUR 1.14 billion on revenue up 4.33% to EUR 2.87 billion
Reuters  ·  03-20
BioNTech FY 2025 net loss widens 70.83% to EUR 1.14 billion on revenue up 4.33% to EUR 2.87 billion
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
MT Newswires Live  ·  03-19
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
TIPRANKS  ·  03-19
Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
BioNTech SE director Michael Motschmann files initial beneficial ownership statement
Reuters  ·  03-19
BioNTech SE director Michael Motschmann files initial beneficial ownership statement
BioNTech SE files Form 3 as director Helmut Wolfgang Jeggle reports 332,316 ordinary shares
Reuters  ·  03-19
BioNTech SE files Form 3 as director Helmut Wolfgang Jeggle reports 332,316 ordinary shares
BioNTech SE files Form 3 initial beneficial ownership statement for Chief Medical Officer Ozlem Tureci
Reuters  ·  03-19
BioNTech SE files Form 3 initial beneficial ownership statement for Chief Medical Officer Ozlem Tureci
BioNTech SE director Ulrich Wandschneider files initial beneficial ownership statement
Reuters  ·  03-19
BioNTech SE director Ulrich Wandschneider files initial beneficial ownership statement

Introduction

Company Name.
BioNTech SE
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Issue price:
--